Zoonotic Cutaneous Anthrax – A Complete Patient‑Friendly Guide

Overview

Cutaneous anthrax is the most common form of anthrax infection in humans, accounting for roughly 95% of reported cases. It occurs when spores of the bacterium Bacillus anthracis enter the skin through a cut, abrasion, or puncture wound. When the source of spores is an infected animal (usually livestock such as cattle, sheep, goats, or wild herbivores) the disease is termed zoonotic cutaneous anthrax.

Although anthrax is a worldwide disease, human cases are rare in developed nations. In the United States, the CDC recorded an average of 5–6 cutaneous cases per year between 2000‑2022, whereas endemic regions of sub‑Saharan Africa, Central Asia, and parts of South America report hundreds of cases annually, often linked to occupational exposure.

Anyone who works closely with potentially infected animals or animal products—farmers, veterinarians, meat‑processing workers, and hunters—is most at risk, but tourists who handle hides or attend livestock markets can also become infected.

Symptoms

Symptoms usually appear 2–7 days after exposure, but incubation can range from 1–14 days.

• Initial papule – a painless, raised bump (1‑2 cm) that resembles an insect bite.
• Vesicle formation – within 24‑48 hours the papule may fill with clear fluid, resembling a blister.
• Ulcer with black eschar – the vesicle ruptures, creating a painless ulcer with a characteristic thick, black “eschar” (scab) in the center. The surrounding skin is often edematous and may be erythematous.
• Edema and lymphadenopathy – swelling can spread to surrounding tissues and regional lymph nodes (e.g., axillary, inguinal) may become enlarged and tender.
• Systemic signs (rare in isolated cutaneous disease) – low‑grade fever, malaise, headache, or myalgia can occur, especially if the infection spreads to the bloodstream (septicemia).

Because the ulcer is usually painless, patients may delay seeking care, mistaking it for a minor skin injury.

Causes and Risk Factors

What causes zoonotic cutaneous anthrax?

The disease is caused by Bacillus anthracis, a gram‑positive, spore‑forming bacterium. Spores are highly resistant to heat, UV light, and desiccation, allowing them to survive in soil for decades. When an animal dies of anthrax, the spores are released into the environment, contaminating soil, water, vegetation, and animal hides.

Key risk factors

• Occupational exposure – livestock handlers, veterinarians, abattoir workers, and leather tanners.
• Handling infected carcasses – skinning, butchering, or disposal of dead animals without protective gear.
• Contact with contaminated animal products – raw hides, wool, hair, bone meal, or contaminated feed.
• Travel to endemic regions – especially rural agricultural zones where anthrax is not well‑controlled.
• Skin breaks – cuts, abrasions, or needle punctures increase susceptibility.
• Immunocompromise – patients with HIV, diabetes, or on immunosuppressive therapy may have a higher risk of progression to systemic disease.

Diagnosis

Accurate diagnosis relies on a combination of clinical suspicion and laboratory confirmation.

Clinical assessment

• History of animal exposure or work in high‑risk settings.
• Typical painless ulcer with black eschar and surrounding edema.

Laboratory tests

• Microscopy – Gram stain of ulcer swab or tissue shows large, gram‑positive rods without obvious capsule.
• Culture – Blood agar grows non‑hemolytic, gray colonies within 24 h; confirmatory tests include gamma‑phage lysis, penicillin‑binding assay, or MALDI‑TOF.
• Polymerase chain reaction (PCR) – Rapid detection of B. anthracis DNA from skin samples, blood, or tissue. PCR is the preferred method when rapid confirmation is needed.
• Serology – Detection of anti‑protective antigen (PA) antibodies can support diagnosis, especially in later stages.
• Blood cultures – Indicated if systemic symptoms develop; helps identify secondary septicemia.

Because anthrax is a potential bioterror agent, laboratories follow strict biosafety Level 3 (BSL‑3) protocols when handling specimens.

Treatment Options

Prompt antimicrobial therapy dramatically reduces mortality (from >80% in untreated systemic disease to <5% with treatment).

First‑line antibiotics

• Ciprofloxacin 500 mg orally twice daily for 7‑10 days.
• Doxycycline 100 mg orally twice daily for 7‑10 days.
• Either drug may be used intravenously for severe cases or when oral absorption is unreliable.

Alternative agents (for penicillin‑allergic patients or resistant strains)

• Clindamycin 600 mg IV/PO every 8 h.
• Levofloxacin 750 mg orally daily.

Adjunctive therapies

• Surgical debridement – Rarely needed for cutaneous disease but may be required if there is extensive necrosis or secondary bacterial infection.
• Antitoxin – Anthrax immune globulin (AIG) or monoclonal antibodies (e.g., raxibacumab) are reserved for severe systemic disease; not routinely used for uncomplicated cutaneous lesions.

Lifestyle and supportive care

• Keep the lesion clean and covered with a sterile dressing.
• Maintain adequate hydration and nutrition.
• Avoid smoking and excessive alcohol, which can impair wound healing.

Living with Zoonotic Cutaneous Anthrax

Most patients recover fully with appropriate antibiotics, but there are practical steps to support healing and prevent relapse.

• Wound care – Change dressings daily, use mild antiseptic (e.g., chlorhexidine) if advised by your clinician.
• Monitor for spread – Check surrounding skin for new lesions or increasing redness.
• Medication adherence – Complete the full course of antibiotics even if the sore looks healed.
• Follow‑up appointments – Usually at 1 and 2 weeks post‑treatment to ensure resolution.
• Work restrictions – Discuss with your employer; many can return to normal duties after 48 h of effective therapy and when the lesion is covered.
• Psychological impact – The stigma of a “bioterror” disease can cause anxiety; seek counseling if needed.

Prevention

Because anthrax is a zoonosis, prevention focuses on breaking the animal‑to‑human transmission cycle.

• Vaccinate livestock – In endemic areas, use the Sterne or live‑attenuated vaccine for cattle, sheep, and goats (recommended by WHO and OIE).
• Use personal protective equipment (PPE) – Gloves, disposable gowns, and eye protection when handling carcasses or raw hides.
• Proper carcass disposal – Burn or deep‑burry infected animals; never open an anthrax‑suspected carcass without veterinary guidance.
• Hand hygiene – Wash hands with soap and water after any animal contact.
• Food safety – Cook meat to an internal temperature of at least 71 °C (160 °F); avoid milk from animals that have not been pasteurized.
• Public health reporting – Veterinarians and physicians should promptly notify local health authorities if anthrax is suspected.

Complications

If left untreated, cutaneous anthrax can progress to severe disease.

• Systemic (inhalational or gastrointestinal) anthrax – Bacterial spread via lymphatics into the bloodstream.
• Septicemia – High fever, hypotension, multi‑organ failure; mortality >85% without aggressive therapy.
• Extensive tissue necrosis – May require surgical excision or skin grafting.
• Scarring – The black eschar often heals with a depressed, sometimes hypertrophic scar.
• Secondary bacterial infection – Staphylococcus or Streptococcus superinfection can delay healing.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. Anthrax: Basic Information. Updated 2023.
• Mayo Clinic. Anthrax – Symptoms and Causes. 2022.
• World Health Organization. Anthrax Fact Sheet. 2021.
• Cleveland Clinic. Anthrax Overview. 2022.
• NIH National Institute of Allergy and Infectious Diseases. Anthrax Research and Treatment. 2023.
• Turner, A. et al. “Cutaneous Anthrax: Clinical Features, Diagnosis, and Management.” *The Lancet Infectious Diseases*, vol. 22, no. 4, 2022, pp. 456‑465.